Johnson & Johnson Operating Income 2010-2024 | JNJ
Johnson & Johnson annual/quarterly operating income history and growth rate from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Johnson & Johnson operating income for the quarter ending September 30, 2024 was $3.338B, a 36.02% decline year-over-year.
- Johnson & Johnson operating income for the twelve months ending September 30, 2024 was $17.626B, a 38.56% increase year-over-year.
- Johnson & Johnson annual operating income for 2023 was $15.062B, a 22.2% decline from 2022.
- Johnson & Johnson annual operating income for 2022 was $19.359B, a 0.94% increase from 2021.
- Johnson & Johnson annual operating income for 2021 was $19.178B, a 16.25% increase from 2020.
Johnson & Johnson Annual Operating Income
(Millions of US $) |
| 2023 |
$15,062 |
| 2022 |
$19,359 |
| 2021 |
$19,178 |
| 2020 |
$16,497 |
| 2019 |
$17,328 |
| 2018 |
$17,999 |
| 2017 |
$17,673 |
| 2016 |
$19,803 |
| 2015 |
$19,196 |
| 2014 |
$20,563 |
| 2013 |
$15,471 |
| 2012 |
$13,775 |
| 2011 |
$12,361 |
| 2010 |
$16,947 |
| 2009 |
$15,755 |
Johnson & Johnson Quarterly Operating Income
(Millions of US $) |
| 2024-09-30 |
$3,338 |
| 2024-06-30 |
$5,748 |
| 2024-03-31 |
$3,714 |
| 2023-12-31 |
$4,826 |
| 2023-09-30 |
$5,217 |
| 2023-06-30 |
$6,306 |
| 2023-03-31 |
$-1,287 |
| 2022-12-31 |
$2,485 |
| 2022-09-30 |
$5,172 |
| 2022-06-30 |
$5,840 |
| 2022-03-31 |
$5,862 |
| 2021-12-31 |
$1,238 |
| 2021-09-30 |
$3,849 |
| 2021-06-30 |
$6,662 |
| 2021-03-31 |
$7,429 |
| 2020-12-31 |
$1,647 |
| 2020-09-30 |
$4,401 |
| 2020-06-30 |
$3,940 |
| 2020-03-31 |
$6,509 |
| 2019-12-31 |
$4,218 |
| 2019-09-30 |
$1,647 |
| 2019-06-30 |
$7,041 |
| 2019-03-31 |
$4,422 |
| 2018-12-31 |
$3,122 |
| 2018-09-30 |
$4,423 |
| 2018-06-30 |
$4,973 |
| 2018-03-31 |
$5,481 |
| 2017-12-31 |
$2,560 |
| 2017-09-30 |
$4,790 |
| 2017-06-30 |
$4,748 |
| 2017-03-31 |
$5,575 |
| 2016-12-31 |
$4,324 |
| 2016-09-30 |
$5,281 |
| 2016-06-30 |
$4,904 |
| 2016-03-31 |
$5,294 |
| 2015-12-31 |
$3,758 |
| 2015-09-30 |
$4,122 |
| 2015-06-30 |
$5,741 |
| 2015-03-31 |
$5,575 |
| 2014-12-31 |
$2,703 |
| 2014-09-30 |
$6,810 |
| 2014-06-30 |
$5,626 |
| 2014-03-31 |
$5,424 |
| 2013-12-31 |
$2,750 |
| 2013-09-30 |
$3,667 |
| 2013-06-30 |
$4,793 |
| 2013-03-31 |
$4,261 |
| 2012-12-31 |
$3,100 |
| 2012-09-30 |
$3,595 |
| 2012-06-30 |
$2,035 |
| 2012-03-31 |
$5,045 |
| 2011-12-31 |
$318 |
| 2011-09-30 |
$4,111 |
| 2011-06-30 |
$3,422 |
| 2011-03-31 |
$4,510 |
| 2010-12-31 |
$2,228 |
| 2010-09-30 |
$4,219 |
| 2010-06-30 |
$4,220 |
| 2010-03-31 |
$6,280 |
| 2009-12-31 |
$2,604 |
| 2009-09-30 |
$4,245 |
| 2009-06-30 |
$4,263 |
| 2009-03-31 |
$4,643 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
